XML 38 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING, INTEGRATION AND OTHER COSTS (Tables)
 6 Months Ended
Jun. 30, 2014
B&L
  
Cost-rationalization and integration initiatives  
Schedule of major components of restructuring costs incurred in connection with acquisition-related initiatives
The following table summarizes the major components of the $232.8 million of restructuring costs, plus the $52.8 million of charges described in the preceding paragraph, incurred in connection with the B&L Acquisition since the acquisition date through June 30, 2014:
 
 
Employee Termination Costs
 
IPR&D
Termination
Costs
 
Contract
Termination,
Facility Closure
and Other Costs
 
 
 
Severance and
Related Benefits
 
Share-Based
Compensation(1)
 
 
 
Total
Balance, January 1, 2013
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

Costs incurred and/or charged to expense
 
155.7

 
52.8

 
—

 
25.6

 
234.1

Cash payments
 
(77.8
)
 
(52.8
)
 
—

 
(7.8
)
 
(138.4
)
Non-cash adjustments
 
11.4

 
—

 
—

 
(6.8
)
 
4.6

Balance, December 31, 2013
 
89.3

 
—

 
—

 
11.0

 
100.3

Costs incurred and/or charged to expense
 
22.5

 
—

 
—

 
6.6

 
29.1

Cash payments
 
(50.9
)
 
—

 
—

 
(3.2
)
 
(54.1
)
Non-cash adjustments
 
(2.3
)
 
—

 
—

 
(3.1
)
 
(5.4
)
Balance, March 31, 2014
 
58.6

 
—

 
—

 
11.3

 
69.9

Costs incurred and charged to expense
 
12.3

 
—

 
—

 
10.1

 
22.4

Cash payments
 
(25.7
)
 
—

 
—

 
(1.8
)
 
(27.5
)
Non-cash adjustments
 
(0.5
)
 
—

 
—

 
(0.4
)
 
(0.9
)
Balance, June 30, 2014
 
$
44.7

 
$
—

 
$
—

 
$
19.2

 
$
63.9

___________________________________
(1)
Relates to B&L’s previously cancelled performance-based options and the acceleration of unvested stock options for B&L employees as a result of the B&L Acquisition.
Medicis
  
Cost-rationalization and integration initiatives  
Schedule of major components of restructuring costs incurred in connection with acquisition-related initiatives
The following table summarizes the major components of the $109.2 million of restructuring costs, plus the charge of $77.3 million described in the preceding paragraph, incurred in connection with the Medicis acquisition since the acquisition date through June 30, 2014:
 
 
Employee Termination Costs
 
IPR&D
Termination
Costs
 
Contract
Termination,
Facility Closure
and Other Costs
 
 
 
Severance and
Related Benefits
 
Share-Based
Compensation(1)
 
 
 
Total
Balance, January 1, 2012
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

Costs incurred and/or charged to expense
 
85.3

 
77.3

 
—

 
0.4

 
163.0

Cash payments
 
(78.0
)
 
(77.3
)
 
—

 
—

 
(155.3
)
Non-cash adjustments
 
4.1

 
—

 
—

 
(0.2
)
 
3.9

Balance, December 31, 2012
 
11.4

 
—

 
—

 
0.2

 
11.6

Costs incurred and/or charged to expense
 
20.0

 
—

 
—

 
3.5

 
23.5

Cash payments
 
(31.4
)
 
—

 
—

 
(3.6
)
 
(35.0
)
Non-cash adjustments
 
0.3

 
—

 
—

 
(0.1
)
 
0.2

Balance, December 31, 2013(2)
 
$
0.3

 
$
—

 
$
—

 
$
—

 
$
0.3

____________________________________
(1)
Relates to the acceleration of unvested stock options, restricted stock awards, and share appreciation rights for Medicis employees that was triggered by the change in control.

(2)
The Company has not recognized any restructuring charges, and made a payment of $0.1 million, in the six-month period ended June 30, 2014 with respect to the Medicis acquisition-related initiatives. In the six-month period ended June 30, 2013, the Company recognized $21.0 million of restructuring charges and made payments of $31.9 million.